https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Consensus statements for management of Barrett's Dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12780 Sat 24 Mar 2018 08:18:20 AEDT ]]> Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12781 90% decrease in mean eosinophil count) was observed in 11 of 15 subjects who received 6 weeks of fluticasone (62%), compared with none of the 15 subjects who received placebo (P < .001), based on intention-to-treat analysis; histologic responses were observed in 68% of subjects who received fluticasone (13 of 19) compared with none of those who received placebo (0 of 15) by per-protocol analysis (P < .001). Intracellular staining for eosinophil-derived neurotoxin was reduced in 81% of subjects who received fluticasone (13 of 16) compared with 8% who received placebo (1 of 13) (P < .001). Dysphagia was reduced in 57% of subjects who received fluticasone (12 of 21) compared with 33% who received placebo (7 of 21) (P = .22) by intention-to-treat analysis; dysphagia was reduced in 63% of patients who received fluticasone (12 of 19) and 47% of those who received placebo (7 of 15) (P = .49) based on per-protocol analysis. Esophageal candidiasis developed in 26% of subjects who received fluticasone (5 of 19), but in none of the subjects in the placebo group (P = .05). Aerosolized, swallowed fluticasone leads to a histologic but not a symptomatic response in adults with EoE.]]> Sat 24 Mar 2018 08:18:19 AEDT ]]>